Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis

Neurological Sciences

Volumn 36, Issue 8, 2015, Pages 1319-1329

  Xie, Cheng long ^a,d   Zhang, Yun Yun ^b   Wang, Xiao Dan ^c   Chen, Jie ^a   Chen, Yi He ^a   Pa, Jia Lin ^a   Lin, Shi Yi ^a   Lin, Hua Zhen ^a   Wang, Wen Wen ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Initial treatment; l Dopa; l Dopa sparing therapy; Meta analysis; Parkinson s disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; MONOAMINE OXIDASE TYPE B INHIBITOR; PRAMIPEXOLE; ROPINIROLE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT;

CONSTIPATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; EDEMA; FOLLOW UP; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; META ANALYSIS; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; ADJUVANT CHEMOTHERAPY; ANIMAL; BIBLIOGRAPHIC DATABASE; CONSERVATIVE TREATMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANIMALS; ANTIPARKINSON AGENTS; CHEMOTHERAPY, ADJUVANT; DATABASES, BIBLIOGRAPHIC; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; ORGAN SPARING TREATMENTS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938202294     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-015-2253-7     Document Type: Review

References (27)

1. Marsh L, Dawson TM (2000) Treatment of early Parkinson’s disease. BMJ 321(7252):1–2
2. Brotchie J, Fitzer-Attas C (2009) Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 72(7 Suppl):S32–S38
3. Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311(16):1670–1683
4. Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508
5. Stowe RL, Ives NJ, Clarke C, et al. (2008) Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev (2):CD006564. doi:10.1002/14651858.CD006564
6. Stern MB (2004) Dopamine agonists modify the course of Parkinson disease. Arch Neurol 61(12):1969–1971
7. Utsumi H, Okuma Y, Kano O et al (2013) Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson’s disease. Intern Med 52(3):325–332
8. Lang AE, Marras C (2014) Initiating dopaminergic treatment in Parkinson’s disease. Lancet 384(9949):1164–1166
9. Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484–1491
10. Pd Med Collaborative Group (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384(9949):1196–1205
11. Oertel WH, Wolters E, Sampaio C et al (2006) Pergolide vs levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 21(3):343–353
12. Vesterinen HM, Sena ES, Egan KJ et al (2014) Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods 221:92–102
13. Rinne UK, Bracco F, Chouza C et al (1998) Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):23–30
14. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284(15):1931–1938
15. Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484–1491
16. Caraceni T, Musicco M (2001) Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson’s disease. A randomized multicenter study. Parkinsonism Relat Disord 7(2):107–114
17. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653–1661
18. Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61(7):1044–1053
19. Hauser RA, Rascol O, Korczyn AD et al (2007) Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22(16):2409–2417
20. Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66(5):563–570
21. Utsumi H, Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group (2012) Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson’s disease: a 5-year prospective study. Acta Med Okayama 66(2):163–170
22. Storch A, Wolz M, Beuthien-Baumann B et al (2013) Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology 80(19):1754–1761
23. Oguh O, Kwasny M, Carter J et al (2013) Caregiver strain in Parkinson’s disease: national Parkinson Foundation Quality Initiative study. Parkinsonism Relat Disord 19(11):975–979
24. Ferreira JJ, Katzenschlager R, Bloem BR et al (2013) Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 20(1):5–15
25. Olanow CW, Schapira AH (2013) Therapeutic prospects for Parkinson disease. Ann Neurol 74(3):337–347
26. Katzenschlager R, Head J, Schrag A et al (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71(7):474–480
27. Parashos SA, Luo S, Biglan KM et al (2014) Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol 71(6):710–716